Filspari denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for filspari are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Imposes Quantity Limits on Filspari — and How to Appeal Them

Aetna's quantity limit for Filspari (sparsentan) is set to align with the FDA-approved prescribing label's recommended dosing regimen. If a prescription as written exceeds that limit — for example, because of a dosing adjustment, titration schedule, or supply-quantity preference — the claim will reject. Quantity-limit denials for a drug used at its approved dose are among the more straightforward appeal categories, because the FDA prescribing label itself is the benchmark and the appeal is essentially a documentation exercise.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline on your denial notice. Quantity-limit appeals are typically resolved at the first internal appeal level.
• External review: Available after internal appeal denial. The standard window is approximately four months from the original denial.
• Expedited review: If active disease progression makes delay harmful, request expedited processing.

## Documentation to Gather

1. Prescription as written — confirm the dose and quantity your prescriber ordered and how it compares to the FDA-approved label's recommended regimen. 2. FDA prescribing label — attach the relevant section of the Filspari prescribing information showing the approved dosing. If the quantity matches the label, this directly rebuts the denial. 3. Clinical rationale for any deviation — if the quantity exceeds what Aetna's system expects, your prescriber must document the clinical reason (e.g., titration phase, supply-day adjustment, or other clinically driven factor). 4. Diagnosis and ongoing necessity — current IgAN diagnosis, kidney function trend, and proteinuria status confirming continued medical necessity for ongoing treatment. 5. Prescriber medical-necessity letter — explaining the dosing rationale and referencing the FDA label.

## Criteria-Mapping Structure

Request Aetna's quantity-limit criteria for Filspari from the plan's published clinical policy. Then build a response grid:

| Quantity-Limit Criterion | Your Evidence | |---|---| | Prescribed quantity vs. FDA-label regimen | [FDA label dosing section + prescription copy] | | Diagnosis confirmed and active treatment | [Chart notes + biopsy report date] | | Clinical rationale for quantity | [Prescriber letter — if deviation from label] | | Specialty prescriber involved | [Nephrologist NPI] |

If the prescribed quantity is exactly consistent with the FDA label, lead your appeal with that single exhibit. A brief, direct cover letter noting that the denial contradicts the FDA-approved regimen is often sufficient to resolve a quantity-limit denial at the first appeal level.